DOP2001000210A - USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS - Google Patents

USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Info

Publication number
DOP2001000210A
DOP2001000210A DO2001000210A DO2001000210A DOP2001000210A DO P2001000210 A DOP2001000210 A DO P2001000210A DO 2001000210 A DO2001000210 A DO 2001000210A DO 2001000210 A DO2001000210 A DO 2001000210A DO P2001000210 A DOP2001000210 A DO P2001000210A
Authority
DO
Dominican Republic
Prior art keywords
vapes
organ fibrosis
fibrosis
parapoxvirus ovis
against organ
Prior art date
Application number
DO2001000210A
Other languages
Spanish (es)
Inventor
Olaf Weber
Claudia Hirt-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DOP2001000210A publication Critical patent/DOP2001000210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a medicament having a preventive or curative effect on organ fibrosis in humans.SOLUTION: The medicament shows the effect to a common final path to all diseases connected to fibrosis, using the fact that a preparation of parapoxviruses, obtained from the strains D 1701, orf-11, Greek orf strain 176, Greek orf strain 155, and the New Zealand (NZ) strains inhibit transformation of hepatic stellate cells into collagen producing-myofibroblast type.
DO2001000210A 2000-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS DOP2001000210A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (en) 2000-07-11 2001-05-08 Use of strains of the Parapoxvirus ovis against organ fibrosis

Publications (1)

Publication Number Publication Date
DOP2001000210A true DOP2001000210A (en) 2002-12-15

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000210A DOP2001000210A (en) 2000-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Country Status (14)

Country Link
JP (2) JP5587950B2 (en)
KR (1) KR100845643B1 (en)
CN (1) CN101444539B (en)
AT (1) ATE445413T1 (en)
BR (1) BRPI0112411B8 (en)
DE (2) DE10122233A1 (en)
DK (1) DK1303302T3 (en)
DO (1) DOP2001000210A (en)
EC (1) ECSP034420A (en)
ES (1) ES2332355T3 (en)
PE (1) PE20020218A1 (en)
PT (1) PT1303302E (en)
SV (1) SV2002000527A (en)
ZA (1) ZA200300276B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (en) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant Orf virus vector
EA201891848A1 (en) * 2016-02-16 2019-02-28 Осака Юниверсити PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (en) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
PT885013E (en) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr USE OF MULTI-POTENTIAL INDUCTORS BASED ON POXVIRUSES OR PARAPOXVIRUS ATENUATED AND NOT IMMUNOGENIC FOR THE MANUFACTURE OF MEDICINES

Also Published As

Publication number Publication date
BRPI0112411B8 (en) 2021-05-25
SV2002000527A (en) 2002-10-24
DK1303302T3 (en) 2010-02-08
ES2332355T3 (en) 2010-02-03
JP2014196329A (en) 2014-10-16
KR20030019562A (en) 2003-03-06
KR100845643B1 (en) 2008-07-10
ZA200300276B (en) 2004-04-13
BRPI0112411B1 (en) 2018-02-27
BR0112411A (en) 2003-05-27
JP5587950B2 (en) 2014-09-10
PE20020218A1 (en) 2002-05-19
DE10122233A1 (en) 2002-01-24
CN101444539A (en) 2009-06-03
ECSP034420A (en) 2003-03-10
ATE445413T1 (en) 2009-10-15
PT1303302E (en) 2009-11-11
JP5950964B2 (en) 2016-07-13
JP2012214492A (en) 2012-11-08
CN101444539B (en) 2016-07-06
DE50115181D1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
DE69520768D1 (en) Pharmaceutical preparations containing fluoxetine
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
CA2283280A1 (en) Reovirus for the treatment of neoplasia
DK1418942T3 (en) Poxvirus-containing compositions and processes for their preparation
CA2281193A1 (en) Use of at least one extract of rosaceae, genus sanguisorba officinalis, to promote pigmentation of the skin, hair and/or body hair
ES2127613T3 (en) USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDDES OF NEUROGENOUS ORIGIN.
DOP2001000210A (en) USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
AU2309102A (en) Dermatological formulations
PT1091740E (en) SEMI-SOLID AQUEOUS PREPARATIONS FOR ORAL ADMINISTRATION OF TOLTRAZURIL-SULFONE
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
MXPA05005911A (en) Use of docosahexanoic acid as active substance for the treatment of lipodystrophy.
NO20013605L (en) Preparation for warts
TR200200724T2 (en) Use of fatty acid / amino acid soaps to increase the antimicrobial effect of pharmaceutical compositions that can be applied to the skin
EP1038529A3 (en) Agent for increasing chemokine production
Akbar et al. Quercus infectoria G. Olivier (Fagaceae) (Syns.: Q. boissieri Reut.; Q. carpinea Kotschy ex A. DC; Q. grosseserrata Kotschy ex Wenz.; Q. puberula O. Schwarz; Q. thirkeana K. Koch)
Vazquez How low can you go
ES2130069B1 (en) PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF THE ACTIVE PRODUCT.
Matts et al. The ‘‘dry skin cycle’’: introducing a new model for the induction and propagation of xerosis in normal skin
BRPI0705224A2 (en) use of pau ferro extract (caesalpinia ferrea mart.) in cosmetic and pharmaceutical formulations as a depigmenting / skin whitening agent
GEP20002176B (en) Ointment “Bentastatin” for Treatment of Fungus Diseases of Skin and Mucous Membrane and Inflammatory Processes
AP2001002323A0 (en) The use of aqueous herbal preparation, pmz10, as an alternative remedy in the treatment of HIV/AIDS.
AR031146A1 (en) A STABLE COMPOSITION FOR THE TOPICAL TREATMENT OF SKIN ULCERS OF THE TYPE THAT CORRESPONDS TO A GEL OR MUCILAGINOUS MASS AND PROCEDURE FOR PREPARATION
GEU2001773Y (en) Medicinal Means of Antioxidant Activity
IT1274733B (en) Strain of the genus Lactobacillus of human origin and its uses